Short Interest in Aligos Therapeutics, Inc. (NASDAQ:ALGS) Expands By 23.7%

Aligos Therapeutics, Inc. (NASDAQ:ALGS) was the recipient of a significant increase in short interest in the month of February. As of February 15th, there was short interest totalling 713,000 shares, an increase of 23.7% from the January 31st total of 576,400 shares. Based on an average daily volume of 363,700 shares, the days-to-cover ratio is currently 2.0 days. Currently, 27.0% of the shares of the stock are sold short.

Aligos Therapeutics Stock Down 6.4 %

ALGS opened at $13.48 on Friday. The stock has a market cap of $48.37 million, a PE ratio of -1.01 and a beta of 2.52. Aligos Therapeutics has a 52 week low of $6.76 and a 52 week high of $46.80. The business’s fifty day simple moving average is $27.81 and its 200 day simple moving average is $20.50.

Institutional Trading of Aligos Therapeutics

Institutional investors have recently added to or reduced their stakes in the business. Drive Wealth Management LLC purchased a new stake in Aligos Therapeutics during the fourth quarter valued at about $916,000. Golden State Wealth Management LLC purchased a new stake in Aligos Therapeutics during the fourth quarter valued at about $107,000. AlphaMark Advisors LLC boosted its position in Aligos Therapeutics by 1,000.0% during the fourth quarter. AlphaMark Advisors LLC now owns 1,100 shares of the company’s stock valued at $44,000 after buying an additional 1,000 shares during the period. Northern Trust Corp purchased a new stake in Aligos Therapeutics during the fourth quarter valued at about $205,000. Finally, Tower Research Capital LLC TRC boosted its position in Aligos Therapeutics by 2,073.3% during the fourth quarter. Tower Research Capital LLC TRC now owns 652 shares of the company’s stock valued at $26,000 after buying an additional 622 shares during the period. 60.43% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Separately, HC Wainwright reissued a “buy” rating and issued a $75.00 target price on shares of Aligos Therapeutics in a research note on Thursday, November 7th.

About Aligos Therapeutics

Aligos Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH).